Unlike other top markets, Switzerland has more flexible regulations when it comes to hemp cultivation and THC content, meaning that flowers are widely available, which is one of the top categories in the country. While the market appears to be evolving positively, and many new cannabinoid products are also entering, there seems to be limited fluctuation in price. This report covers a wide range of topics, including product and pricing analysis.
If you purchase a report that is updated in the next 60 days, we will send you the new report for free.
Reasons to buyIf the Swiss market is of interest to you, then this report is for you. You will obtain valuable data and analysis, as well as our insight into the current market, with information about brands and categories, product changes, price fluctuations and up-to-date information about a number of new additional cannabinoid products that have recently entered the Swiss market, all of which will allow you to benchmark your product against competitors.
Table of contents*This report doesn’t offer marketing lists
MethodologyUsing in-house data on the most common brands in both the online and offline markets, 37 unique brands were identified as the most representative in the Swiss market. Together, they form the sample used to analyse the offerings and pricing of CBD products throughout Switzerland. Where available from brand sources, product offerings were collected along with their RRPs. Where data was not available from brand sources, data from e-commerce websites was collected.
Latest reportsUnlike other top markets, Switzerland has more flexible regulations when it comes to hemp cultivation and THC content, meaning that flowers are widely available, which is one of the top categories in the country. While the market appears to be evolving positively, and many new cannabinoid products are also entering, there seems to be limited fluctuation in price. This report covers a wide range of topics, including product and pricing analysis.
Sign up to access our business and regulatory briefings and get the most updated news, insights and our expert analysis to keep you on top of worldwide industry trends.
By signing up you agree to our Terms and Conditions Please note trial access may take up to 24 hours to be granted as access must be qualified by a member of the CBD-Intel team.